Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 2:00 pm ET in Boston, MA.
加利福尼亚州南旧金山，2024年11月4日（GLOBE NEWSWIRE）——Alumis Inc.（纳斯达克股票代码：ALMS）是一家临床阶段的生物制药公司，使用精准方法开发口服疗法，以优化临床结果并显著改善免疫介导疾病患者的生活。该公司今天宣布，Alumis总裁兼首席执行官马丁·巴布勒将参加在古根海姆举行的炉边谈话将于美国东部时间2024年11月12日星期二下午2点在马萨诸塞州波士顿举行的首届医疗创新会议。
A live webcast will be available on the Alumis website in the "Investors" section under the "Events" page. A replay of the conference webcast will be archived on the company's website for 90 days.
将在Alumis网站上的 “投资者” 部分的 “活动” 页面上进行网络直播。会议网络直播的重播将在公司网站上存档90天。
About Alumis
Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. Leveraging its proprietary precision data analytics platform, Alumis is building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases as monotherapy or combination therapies. Alumis' most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 (TYK2) that is currently being evaluated for the treatment of patients with moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Alumis is also developing A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases. Beyond TYK2, Alumis' proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify its precision approach. Incubated by Foresite Labs and led by a team of industry veterans experienced in small-molecule compound drug development for immune-mediated diseases, Alumis is pioneering a precision approach to drug development to potentially produce the next generation of treatment to address immune dysfunction. For more information, visit .
关于 Alumis
Alumis是一家临床阶段的生物制药公司，采用精准方法开发口服疗法，以优化临床结果，显著改善免疫介导疾病患者的生活。利用其专有的精密数据分析平台，Alumis正在建立分子管道，这些分子有可能解决单一疗法或联合疗法等各种免疫介导疾病。Alumis最先进的候选产品ESK-001是一种口服、高选择性、小分子、酪氨酸激酶2（TYK2）的变构抑制剂，目前正在评估其治疗中度至重度斑块状银屑病和系统性红斑狼疮患者。Alumis还在开发 A-005，这是一种穿透CNS的变构TYK2抑制剂，用于治疗神经炎症和神经退行性疾病。除了TYK2，还有Alumis专有的精密数据分析平台和药物发现 专业知识 已促成了其他临床前项目的确定，这些项目可以体现其精确方法。Alumis由Foresite Labs孵化，由一支在免疫介导疾病小分子化合物药物开发方面经验丰富的行业资深人士领导，正在开创一种精准的药物开发方法，有可能生产出解决免疫功能障碍的下一代治疗方法。欲了解更多信息，请访问。
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis' participation at upcoming conferences. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
前瞻性陈述
本新闻稿可能包含前瞻性陈述，包括根据1995年《私人证券诉讼改革法》的安全港条款发表的声明。其中包括但不限于关于Alumis参加即将举行的会议的声明。除非法律要求，否则Alumis明确表示不承担任何更新任何前瞻性陈述的义务。
CONTACT: Alumis Contact Information
Teri Dahlman
Red House Communications
teri@redhousecomms.com
联系人：校友联系信息
泰瑞·达尔曼
红屋通讯
teri@redhousecomms.com
热门市场机会
热门讨论
热门讨论
